Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Gemcitabine, and Bevacizumab in Advanced NSCLC
NCT00378573Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jan 2007
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jan 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00378573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378573.